New study examines immunotherapy outcomes in american indian cancer patients
NCT ID NCT05863052
First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time
Summary
This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The goal is to identify any healthcare disparities and guide future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- immunotherapy
- What this could lead to
- If successful, this could reveal differences in how well immunotherapy works for American Indian patients and point to ways to improve their cancer care.
- What could go wrong
- This is a small, retrospective study that only looks at past data, so it cannot prove cause and effect. Results may not apply to all American Indian populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 72 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
American Indian population is the primary group of interest for this study.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * above age 18, * histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used * received immunotherapy as part of their treatment * Self-identified American Indian in ethnicity * Patients at the Stephenson Cancer Center between 2015 to 2021 Exclusion Criteria: * patients who did not receive immune checkpoint inhibitor therapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastrointestinal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arizona Cancer Center at the Unvieristy of Arizona
Tucson, Arizona, 85719, United States
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Huntsman Cancer Institute at the University of Utah
Salt Lake City, Utah, 84112, United States
-
Monument Health Cancer Care Institute
Rapid City, South Dakota, 57701, United States
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
-
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico, 87102, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New PET tracer aims to light up hidden cancer targets
- Can immunotherapy before surgery stop early oral cancer from returning?
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a glowing dye show surgeons where head and neck tumors end?
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- Can a new drug shield kidneys from chemotherapy damage?